305 related articles for article (PubMed ID: 30175979)
1. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease.
Huan T; Tran T; Zheng J; Sapkota S; MacDonald SW; Camicioli R; Dixon RA; Li L
J Alzheimers Dis; 2018; 65(4):1401-1416. PubMed ID: 30175979
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics.
Yilmaz A; Geddes T; Han B; Bahado-Singh RO; Wilson GD; Imam K; Maddens M; Graham SF
J Alzheimers Dis; 2017; 58(2):355-359. PubMed ID: 28453477
[TBL] [Abstract][Full Text] [Related]
3. Plasma metabolic profiling of mild cognitive impairment and Alzheimer's disease using liquid chromatography/mass spectrometry.
Liu Y; Li N; Zhou L; Li Q; Li W
Cent Nerv Syst Agents Med Chem; 2014; 14(2):113-20. PubMed ID: 25515716
[TBL] [Abstract][Full Text] [Related]
4. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers.
Sapkota S; Huan T; Tran T; Zheng J; Camicioli R; Li L; Dixon RA
Front Aging Neurosci; 2018; 10():296. PubMed ID: 30333744
[No Abstract] [Full Text] [Related]
6. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.
Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W
J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177
[TBL] [Abstract][Full Text] [Related]
7. Development of isotope labeling LC-MS for human salivary metabolomics and application to profiling metabolome changes associated with mild cognitive impairment.
Zheng J; Dixon RA; Li L
Anal Chem; 2012 Dec; 84(24):10802-11. PubMed ID: 23150892
[TBL] [Abstract][Full Text] [Related]
8. Salivaomics as a Potential Tool for Predicting Alzheimer's Disease During the Early Stages of Neurodegeneration.
François M; Karpe A; Liu JW; Beale D; Hor M; Hecker J; Faunt J; Maddison J; Johns S; Doecke J; Rose S; Leifert WR
J Alzheimers Dis; 2021; 82(3):1301-1313. PubMed ID: 34151801
[TBL] [Abstract][Full Text] [Related]
9. Acyl-Alkyl-Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer's Disease as Identified by Targeted Metabolomics.
Marksteiner J; Oberacher H; Humpel C
J Alzheimers Dis; 2019; 68(2):583-589. PubMed ID: 30814361
[TBL] [Abstract][Full Text] [Related]
10. Development of chemical isotope labeling LC-MS for tissue metabolomics and its application for brain and liver metabolome profiling in Alzheimer's disease mouse model.
Wang X; Han W; Yang J; Westaway D; Li L
Anal Chim Acta; 2019 Mar; 1050():95-104. PubMed ID: 30661596
[TBL] [Abstract][Full Text] [Related]
11. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
Trushina E; Dutta T; Persson XM; Mielke MM; Petersen RC
PLoS One; 2013; 8(5):e63644. PubMed ID: 23700429
[TBL] [Abstract][Full Text] [Related]
12. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning.
Wang Y; Sun Y; Wang Y; Jia S; Qiao Y; Zhou Z; Shao W; Zhang X; Guo J; Zhang B; Niu X; Wang Y; Peng D
Alzheimers Res Ther; 2023 Nov; 15(1):191. PubMed ID: 37925455
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Metabolic Signature Predisposing High Risk Patients with Mild Cognitive Impairment to Converting to Alzheimer's Disease.
Huang YL; Lin CH; Tsai TH; Huang CH; Li JL; Chen LK; Li CH; Tsai TF; Wang PN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681563
[TBL] [Abstract][Full Text] [Related]
15. Widely targeted metabolomics of Alzheimer's disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry.
Muguruma Y; Tsutsui H; Noda T; Akatsu H; Inoue K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():53-66. PubMed ID: 29852382
[TBL] [Abstract][Full Text] [Related]
16. Urine metabolomics phenotyping and urinary biomarker exploratory in mild cognitive impairment and Alzheimer's disease.
Wang Y; Sun Y; Wang Y; Jia S; Qiao Y; Zhou Z; Shao W; Zhang X; Guo J; Song X; Niu X; Peng D
Front Aging Neurosci; 2023; 15():1273807. PubMed ID: 38187356
[TBL] [Abstract][Full Text] [Related]
17. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease.
Peng J; Guo K; Xia J; Zhou J; Yang J; Westaway D; Wishart DS; Li L
J Proteome Res; 2014 Oct; 13(10):4457-69. PubMed ID: 25164377
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
19. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease.
Gómez-Pascual A; Naccache T; Xu J; Hooshmand K; Wretlind A; Gabrielli M; Lombardo MT; Shi L; Buckley NJ; Tijms BM; Vos SJB; Ten Kate M; Engelborghs S; Sleegers K; Frisoni GB; Wallin A; Lleó A; Popp J; Martinez-Lage P; Streffer J; Barkhof F; Zetterberg H; Visser PJ; Lovestone S; Bertram L; Nevado-Holgado AJ; Gualerzi A; Picciolini S; Proitsi P; Verderio C; Botía JA; Legido-Quigley C
Comput Biol Med; 2024 Jun; 176():108588. PubMed ID: 38761503
[TBL] [Abstract][Full Text] [Related]
20. Alterations in metabolic pathways and networks in Alzheimer's disease.
Kaddurah-Daouk R; Zhu H; Sharma S; Bogdanov M; Rozen SG; Matson W; Oki NO; Motsinger-Reif AA; Churchill E; Lei Z; Appleby D; Kling MA; Trojanowski JQ; Doraiswamy PM; Arnold SE;
Transl Psychiatry; 2013 Apr; 3(4):e244. PubMed ID: 23571809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
